One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
1876 articles with Amgen
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis
Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis
Amgen is suing Novartis, alleging a breach of the partnership and seeking to terminate the 2015 contract. Novartis, in response, filed a lawsuit accusing Amgen of inappropriately attempting to end the alliance.
Companies to study advanced approaches to regulatory-grade real world evidence
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations
On day two of Cowen and Company’s 39th Annual Health Care Conference, more companies shared insight into pipeline development. BioSpace rounded up a few of the stories.
Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three
Amgen will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston.
Amgen announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019.
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
Several Real-World Evidence Studies Highlight Continued Unmet Need and Suboptimal Treatment of High-Risk Cardiovascular Disease Patients
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Praluent® (alirocumab) continues to be available in the U.S.
Amgen announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies.
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Amgen (NASDAQ: AMGN),Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.